. 2022 Aug 6;7:272. doi: 10.1038/s41392-022-01134-4

Table 6.

Clinical trials comparing the efficacy of MSCs derived from different sources in the treatment of pulmonary diseases and cardiovascular conditions

Study name	Time	Disease	Intervention			Treatment outcomes	Effective cell sources
Study name	Time	Disease	Source	Dose	Route	Treatment outcomes	Effective cell sources
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial³¹⁵ (NCT00768066)	2014	Ischemic Heart Failure	BM-MSCs Vs. Autologous bone marrow mononuclear cells (aBMNCs)	2 × 10⁸ cells	Transendocardial (TE) injection	TE injection of BM-MSCs or aBMNCs appeared to be safe for patients with chronic cardiomyopathy and left ventricular dysfunction.	No significant difference between two approaches.
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial³¹⁰ (NCT01392625)	2017	Nonischemic Dilated Cardiomyopathy (NIDCM)	Autologous BM-MSCs vs. Allogeneic BM-MSCs.	1 × 10⁸ cells	Transendocardial (TE) injection	The results support the safety profiles of BM-MSCs in the treatment of NIDCM patients.	Allogeneic BM-MSCs
Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial)³²⁵ (NCT02323477)	2020	Myocardial Infarction	Allogeneic UC-MSCs vs. bone marrow mononuclear cells (aBMNCs)	2 × 10⁷ UC-MSCs 20–25 × 10⁷ aBMNCs	intramyocardial injection	Significant results were observed in the intramyocardial delivery of UC-MSCs justified their efficacy in chronic ischemic cardiomyopathy.	UC-MSCs
Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial³¹⁵ (NCT02412332)	2021	Chronic Obstructive Pulmonary Disease	Autologous bone marrow mononuclear cells (aBMNCs) vs. Coinfusion of BMNCs and AT-MSCs.	1 × 10⁸ cells	IV	Safety: No adverse events Efficiency: - BMMC group showed an increase in forced expiratory volume (FEV1) and diffusing capacity for carbon monoxide (DLCO). - Coinfusion group showed a DLCO, and gas exchange improvement and a better quality of life.	No significant difference between two approaches.